Mankind Pharma Sustainability Profile
Mankind Pharma, a prominent player in the Indian pharmaceutical industry, is headquartered in New Delhi, India. Founded in 1991, the company has established itself as a leader in the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including prescription medications, over-the-counter drugs, and consumer healthcare items. With a strong focus on quality and innovation, Mankind Pharma has achieved significant milestones, including rapid expansion across major operational regions in India and beyond. The company is renowned for its unique formulations and commitment to affordable healthcare, positioning itself as a trusted name among healthcare professionals and consumers alike. Notable achievements include a robust market presence and recognition for its contributions to the pharmaceutical sector, making Mankind Pharma a key player in enhancing health outcomes across the region.
DitchCarbon Score
How does Mankind Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mankind Pharma's score of 27 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mankind Pharma's reported carbon emissions
In 2024, Mankind Pharma reported total carbon emissions of approximately 5,831,000 kg CO2e for Scope 1 and about 17,335,000 kg CO2e for Scope 2 emissions globally. This reflects a significant reduction from 2023, where Scope 1 emissions were reported at approximately 14,519,000 kg CO2e. The company has not disclosed any Scope 3 emissions data. Mankind Pharma's emissions intensity for Scope 1 and Scope 2 combined is approximately 0.004805 kg CO2e per rupee of turnover, indicating a focus on improving efficiency in relation to revenue generation. The company has not set specific reduction targets or climate pledges, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi). Overall, Mankind Pharma's commitment to reducing its carbon footprint is evident through its emissions reporting, although further details on reduction initiatives and long-term climate strategies are not available.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 15,753,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 28,074,000 | - | 00,000,000 |
| Scope 3 | 168,000 | - | - |
How Carbon Intensive is Mankind Pharma's Industry?
How Carbon Intensive is Mankind Pharma's Location?
Mankind Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mankind Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
